日本ケミファの株価時系列
日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
---|---|---|---|---|---|---|---|
2023/06/21 | 1,825 | 1,859 | 1,825 | 1,832 | +7 | +0.4% | 2,700 |
2023/06/20 | 1,835 | 1,836 | 1,825 | 1,825 | -10 | -0.5% | 1,400 |
2023/06/19 | 1,835 | 1,835 | 1,829 | 1,835 | +11 | +0.6% | 1,000 |
2023/06/16 | 1,810 | 1,825 | 1,810 | 1,824 | +6 | +0.3% | 4,000 |
2023/06/15 | 1,821 | 1,839 | 1,818 | 1,818 | -10 | -0.5% | 3,300 |
2023/06/14 | 1,833 | 1,833 | 1,825 | 1,828 | +7 | +0.4% | 1,800 |
2023/06/13 | 1,818 | 1,832 | 1,817 | 1,821 | +6 | +0.3% | 2,800 |
2023/06/12 | 1,820 | 1,820 | 1,815 | 1,815 | ±0 | ±0% | 300 |
2023/06/09 | 1,823 | 1,823 | 1,815 | 1,815 | -8 | -0.4% | 3,800 |
2023/06/08 | 1,818 | 1,824 | 1,816 | 1,823 | +5 | +0.3% | 1,800 |
2023/06/07 | 1,826 | 1,830 | 1,817 | 1,818 | -10 | -0.5% | 3,000 |
2023/06/06 | 1,825 | 1,828 | 1,820 | 1,828 | ±0 | ±0% | 1,000 |
2023/06/05 | 1,825 | 1,831 | 1,821 | 1,828 | -1 | -0.1% | 3,100 |
2023/06/02 | 1,825 | 1,834 | 1,818 | 1,829 | +3 | +0.2% | 3,900 |
2023/06/01 | 1,834 | 1,838 | 1,820 | 1,826 | -1 | -0.1% | 2,200 |
2023/05/31 | 1,826 | 1,836 | 1,826 | 1,827 | -1 | -0.1% | 2,600 |
2023/05/30 | 1,850 | 1,850 | 1,828 | 1,828 | -12 | -0.7% | 3,800 |
2023/05/29 | 1,853 | 1,853 | 1,840 | 1,840 | -14 | -0.8% | 3,400 |
2023/05/26 | 1,847 | 1,862 | 1,847 | 1,854 | +7 | +0.4% | 6,100 |
2023/05/25 | 1,845 | 1,858 | 1,841 | 1,847 | +2 | +0.1% | 3,100 |
2023/05/24 | 1,846 | 1,853 | 1,845 | 1,845 | ±0 | ±0% | 2,900 |
2023/05/23 | 1,853 | 1,870 | 1,840 | 1,845 | -32 | -1.7% | 9,000 |
2023/05/22 | 1,827 | 1,895 | 1,827 | 1,877 | +57 | +3.1% | 12,900 |
2023/05/19 | 1,822 | 1,829 | 1,818 | 1,820 | +3 | +0.2% | 1,800 |
2023/05/18 | 1,820 | 1,828 | 1,817 | 1,817 | +1 | +0.1% | 2,100 |
2023/05/17 | 1,814 | 1,825 | 1,814 | 1,816 | +1 | +0.1% | 2,900 |
2023/05/16 | 1,818 | 1,827 | 1,813 | 1,815 | -3 | -0.2% | 1,200 |
2023/05/15 | 1,799 | 1,818 | 1,799 | 1,818 | +11 | +0.6% | 1,700 |
2023/05/12 | 1,811 | 1,813 | 1,798 | 1,807 | -12 | -0.7% | 2,200 |
2023/05/11 | 1,803 | 1,819 | 1,803 | 1,819 | +4 | +0.2% | 300 |
2023/05/10 | 1,822 | 1,822 | 1,800 | 1,815 | -3 | -0.2% | 3,300 |
2023/05/09 | 1,807 | 1,828 | 1,802 | 1,818 | +9 | +0.5% | 2,800 |
2023/05/08 | 1,808 | 1,813 | 1,802 | 1,809 | +1 | +0.1% | 2,300 |
2023/05/02 | 1,800 | 1,810 | 1,791 | 1,808 | -4 | -0.2% | 1,900 |
2023/05/01 | 1,795 | 1,812 | 1,795 | 1,812 | +15 | +0.8% | 1,500 |
2023/04/28 | 1,785 | 1,797 | 1,780 | 1,797 | +9 | +0.5% | 1,300 |
2023/04/27 | 1,801 | 1,805 | 1,788 | 1,788 | -11 | -0.6% | 12,600 |
2023/04/26 | 1,805 | 1,811 | 1,795 | 1,799 | -3 | -0.2% | 3,600 |
2023/04/25 | 1,809 | 1,813 | 1,800 | 1,802 | +1 | +0.1% | 4,100 |
2023/04/24 | 1,810 | 1,810 | 1,801 | 1,801 | -2 | -0.1% | 1,300 |
2023/04/21 | 1,801 | 1,808 | 1,801 | 1,803 | +3 | +0.2% | 1,300 |
2023/04/20 | 1,801 | 1,813 | 1,800 | 1,800 | -1 | -0.1% | 3,600 |
2023/04/19 | 1,814 | 1,814 | 1,796 | 1,801 | -13 | -0.7% | 1,900 |
2023/04/18 | 1,790 | 1,817 | 1,790 | 1,814 | +33 | +1.9% | 5,300 |
2023/04/17 | 1,777 | 1,784 | 1,777 | 1,781 | -5 | -0.3% | 1,600 |
2023/04/14 | 1,801 | 1,808 | 1,778 | 1,786 | -15 | -0.8% | 3,600 |
2023/04/13 | 1,809 | 1,810 | 1,800 | 1,801 | -4 | -0.2% | 2,700 |
2023/04/12 | 1,805 | 1,805 | 1,805 | 1,805 | ±0 | ±0% | 400 |
2023/04/11 | 1,800 | 1,805 | 1,785 | 1,805 | +6 | +0.3% | 7,900 |
2023/04/10 | 1,785 | 1,800 | 1,785 | 1,799 | +17 | +1% | 1,100 |
351~
400
件表示中 / 3586件
類似銘柄と比較する
現在ご覧いただいている「日ケミファ」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
---|---|---|---|---|---|---|---|---|
日ケミファ | 151,100円 | +2.5% | - | 3.31% | 90.86倍 | 0.29倍 |
|
中堅後発薬メーカー。長期収載品の主力は痛風薬ウラリット。新薬開発、検査薬事業を中期強化 |
ティムス | 20,500円 | - | - | 0.00% | - | 2.78倍 |
|
東京農工大発創薬ベンチャー。黒カビ由来の急性期脳梗塞薬候補品を香港拠点ジーシンに導出 |
ノイルイミューン | 17,300円 | -97.8% | - | 0.00% | - | 1.50倍 |
|
独自技術用いたCAR-T細胞免疫療法で抗がん剤を複数開発中。中外製薬とライセンス契約 |
カルナバイオ | 31,000円 | -43.1% | - | 0.00% | - | 1.84倍 |
|
キナーゼタンパク質の販売や受託試験など創薬初期の支援事業が柱。キナーゼ阻害剤で創薬も |
VIS | 89,000円 | +87.8% | +265.7% | 0.00% | 53.45倍 | 2.45倍 |
|
mRNA標的低分子創薬技術を製薬会社に提供。共同創薬研究などによる契約金収入が柱 |
市場注目の銘柄
チャート関連のコラム